Apotex Challenge On Neurontin Generic Exclusivity May Be Too Late – Judges

Apotex' attempt to re-open generic exclusivity for Neurontin may be barred because the company failed to challenge FDA's patent-based approach for awarding 180-day exclusivity in earlier gabapentin litigation, appellate judges suggested Dec. 6